White Guide and Orange Guide Formatting Project - Pfizer

Orange Guide – Chapter 5: Interactions with Health Systems and Medical Groups
Collaborating around Disease States not linked to a Pfizer Product
Q. In a meeting regarding a potential collaboration, a customer raises the
possibility of an obesity project. Since Pfizer doesn’t have a product in this
disease state, can we engage in this discussion?
A. It depends. Collaborations with customers must provide specific,
appropriate and commensurate business value to both the customer and
Pfizer. In certain circumstances collaborations in disease areas where we
do not currently have a product may provide public health objectives that
are aligned with Pfizer’s interests, such as reducing the risk of co-morbid
conditions. In these cases, an obesity project may provide appropriate
business value to Pfizer; however, each project will need to be assessed on
a case-by-case basis. It is critical that you consult with your team attorney
in the concept stage of the process to ensure that the project is
appropriate.
Appropriate Product Discussions
Collaborations
Q. Xalkori is indicated for the treatment of patients with locally advanced or
metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma
kinase (ALK)-positive, as detected by an FDA-approved test. Does that
mean that Oncology commercial colleagues, when discussing disease
state, can only discuss ALK-positive NSCLC?
A. It depends. To the extent the colleague is discussing use of Xalkori in any
way, the colleague must be careful to only discuss ALK-positive NSCLC.
However, to the extent a colleague is discussing a population in a Health
System with NSCLC generally to understand the Health System’s
treatment needs, they would not be required to only discuss the patients
who are ALK-positive since that is not known about the population.
However, any proposed collaboration or project should be discussed with,
and approved by, your team attorney.
A collaboration, generally, is an activity or project undertaken by Pfizer with one or more organizations
to advance public health goals of interest to both Pfizer and the organization(s). Pfizer may provide
funds, resources or expertise to the collaboration. Pfizer is involved to some extent in the creation of
the materials or other activities (e.g., providing suggestions or feedback) and may receive the right to
use the materials or other output created pursuant to the collaboration. The customer or Pfizer, or
105
Rev. 09/12
Page 10 of 18